Synthetic Biology Market Players and Regional Data Coverage Report of 2017MENAFN.COMGlobal Synthetic Biology market value is provided for 2016 in million-dollar offered by the end of 2022, shows a consistent growth between 2016 and 2022. This report st… Continue reading
KCUR |
With GMO Struggle In Mind, Food Industry Vying For Public Trust With CRISPR Discussion
KCUR Dozens of crops and livestock developed with CRISPR technology are years from the market, though the U.S. Department of Agriculture already said it won’t regulate CRISPR-developed products like other genetically engineered food since no foreign genetic … |
KCUR |
With GMO Struggle In Mind, Food Industry Vying For Public Trust With CRISPR Discussion
KCUR Dozens of crops and livestock developed with CRISPR technology are years from the market, though the U.S. Department of Agriculture already said it won’t regulate CRISPR-developed products like other genetically engineered food since no foreign genetic … |
KCUR |
With GMO Struggle In Mind, Food Industry Vying For Public Trust With CRISPR Discussion
KCUR Dozens of crops and livestock developed with CRISPR technology are years from the market, though the U.S. Department of Agriculture already said it won’t regulate CRISPR-developed products like other genetically engineered food since no foreign genetic … |
Maui News |
Maui EMT’s stem cell donation saves Australia woman’s life
Maui News Wearing a T-shirt that reads “My sister’s battle is my battle,” Wailuku EMT Wayne Segundo donates stem cells at the Kapiolani Medical Center for Women & Children on Oahu in March. The donation went to a 39-year-old cancer patient in Australia whom … |
|
Alliance for Cancer Gene Therapy announces $1.3M grant to three scientists
Westfair Online Stamford’s Alliance for Cancer Gene Therapy, the nation’s only nonprofit dedicated exclusively to cell and gene therapies for cancer, has granted $1.3 million to three scientists exploring gene therapy to tackle glioblastoma (brain cancer), sarcoma … |
|
GSK picks up NICE recommendation for Strimvelis, a €594000 gene therapy
FiercePharma Despite being one of the most expensive drugs in the world, GlaxoSmithKline’s gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or “bubble boy” syndrome. The drug, which costs … |